سعر بيكراي 200مجم 28 قرص 2026

Piqray (alpelisib) 200 mg film-coated tablets, pack of 28, Novartis; PI3K-alpha inhibitor for PIK3CA-mutated breast cancer.

• In combination with fulvestrant for adults with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer (detected by an FDA-approved test) following progression on or after an endocrine-based regimen.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=20%, including laboratory abnormalities): increased glucose and creatinine, diarrhoea, rash, decreased lymphocytes, increased GGT/ALT/lipase, nausea, fatigue, decreased haemoglobin, decreased appetite, stomatitis, vomiting, weight loss, decreased calcium, prolonged aPTT and alopecia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe hypersensitivity to alpelisib or any of its components.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe hypersensitivity including anaphylaxis; permanently discontinue in the event of severe hypersensitivity.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe cutaneous adverse reactions (SJS, erythema multiforme, TEN, DRESS); interrupt for suspected SCAR and permanently discontinue if confirmed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe hyperglycaemia, including hyperosmolar non-ketotic syndrome and ketoacidosis (fatal cases post-marketing); hyperglycaemia reported in 65% of patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducersDecrease alpelisib concentrations and may reduce efficacy; avoid.DailyMed (U.S. National Library of Medicine)
• BCRP inhibitorsMay increase alpelisib concentrations and toxicity; avoid or monitor closely.DailyMed (U.S. National Library of Medicine)

• Advise not to breastfeed during treatment and for 1 week after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Alpelisib: Inhibits PI3K, predominantly PI3K-alpha, blocking PI3K/Akt signalling driven by PIK3CA gain-of-function mutations (US label).